A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Genentech, Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
postmenopausal women;
metastatic breast cancer suitable for endocrine therapy;
positive hormone receptor status;
Human epidermal growth factor receptor 2 (HER2) overexpression.
You may not be if
patients on hormone replacement therapy;
previous chemotherapy for metastatic disease;
uncontrolled cardiac disease and history of cardiac failure.
Clareo Health | A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
